Naloxone-induced withdrawal syndrome after administration of selective opioid agonists or after activation of the endogenous enkephalinergic system.
Maldonado
R
R
Lab. Pharmacologie, U266 INSERM, Paris, France.
Waksman
G
G
Feger
J
J
Roques
B P
BP
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D004745:Enkephalins / Q000378:metabolism* / Q000494:pharmacology; D006877:Hydroxamic Acids / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology*; D009294:Narcotics / Q000633:toxicity*; D009842:Oligopeptides / Q000494:pharmacology; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000494:pharmacology; D051381:Rats; D011957:Receptors, Opioid / Q000187:drug effects; D017465:Receptors, Opioid, delta; D017450:Receptors, Opioid, mu; D013375:Substance Withdrawal Syndrome / Q000209:etiology* / Q000378:metabolism / Q000523:psychology; D015431:Weight Loss / Q000187:drug effects
D004745:Enkephalins; D006877:Hydroxamic Acids; D009294:Narcotics; D009842:Oligopeptides; D011957:Receptors, Opioid; D017465:Receptors, Opioid, delta; D017450:Receptors, Opioid, mu; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; C061042:3-(N-hydroxycarboxamido-2-benzylpropanoyl)phenylalanine; C054868:tyrosyl-seryl(O-tert-butyl)-glycyl-phenylalanyl-leucyl-threonine; D009270:Naloxone; D010649:Phenylalanine